June 11, 2018
FDA: Hospira recalls two lots of Naloxone Hydrochloride Injection
Editor's Note
The Food & Drug Administration on June 4 announced the recall by Hospira, Inc, of two lots of its opioid antagonist Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system (NDC 0409-1782-69).
The two lots, 72680LL and 76510LL, were recalled because of the potential presence of embedded and loose particulate matter on the syringe plunger.
To date, Hospira has not received reports of any adverse events associated with these lots.
Free Daily News
- Report: Consistent, purposeful manager-team engagement reduces RN turnover
- Death, hospital readmission less likely for women treated by female doctors
- FDA announces class 1 recalls for infusion pumps, anesthesia workstation
- Study finds workforce readiness gap in new nurses
- Joint replacement manufacturer recalls products after FDA packaging warning
- Gene-edited pig kidney, heart pump combined in transplant surgery milestone
- Catheter sterility concerns prompt Class 1 FDA recall for surgery trays
- Large amounts of personal data possibly stolen in Change Healthcare cyberattack
- AI model helps predict patient decline, drive collaborative care
- One patient’s recovery highlights benefits of outpatient endoscopic spine surgery
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging